New hospital medicines, without price agreements, may be temporarily excluded from the basic package due to high prices. Zorginstituut advises on inclusion, and the minister negotiates prices with the manufacturer. Zorginstituut uses data from Medicines Horizon Scan to recommend medicines for the sluice, which is for high-cost treatments in medical-specialist care within hospitals.
These medicines are still in the approval process. These medicines are included in the sluice candidate letter.
| Active substance | Expected Registration | Indication |
|---|---|---|
| Apitegromab | September 2026 | Add on for patients ≥2 years old, who were previously diagnosed with later-onset spinal muscular atrophy (SMA) (i.e., Type 2 and Type 3 SMA) and are receiving an approved survival motor neuron (SMN) upregulator therapy (i.e., either nusinersen or risdiplam). |
| Lonapegsomatropine | August 2026 | Lonapegsomatropin monotherapy for treatment of adult-onset Growth hormone deficiency in adults over 23 years of age and elderly. |
| Lurbinectedin | August 2027 | Lurbinectedin monotherapy for second line treatment of relapsed Small cell lung cancer in adults and elderly who failed one prior platinum-containing chemotherapy, with or without anti-PD-1 or anti-PD-L1 agents. |
| Lurbinectedin | June 2026 | Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. |
| Nadofaragene firadenovec | June 2026 | Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours. |
| Sargramostim | August 2025 | Imreplys is indicated for treatment of patients of all ages acutely exposed to myelosuppressive doses of radiation with Haematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS]. |
| Sasanlimab | In combination with Bacillus Calmette-Guerin (BCG), for the treatment of patients with BCG-naïve, high-risk, non-muscle invasive bladder cancer (NMIBC). | |
| Tarlatamab | May 2026 | Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. |
| Zamtocabtagene autoleucel | April 2027 | Treatment of adults with large B-cell lymphoma |
| Zamtocabtagene autoleucel | April 2028 | Zamtocabtagene autoleucel monotherapy for third line or later treatment of relapsed/refractory Diffuse large B-cell lymphoma in adults and elderly who are not eligible for high-dose chemotherapy and autologous stem cell transplantation. |
Medicines that are included in the sluice are subject to negotiation between the minister and the manufacturer. Once the medicine is out of the sluice, it is clear whether and at what price the medicine will be reimbursed.
These medicines were still in the sluice in the previous scan. Meanwhile, an agreement has been reached with the manufacturer, it is included in the basic insurance and is registered or reimbursed.